04:25 PM EST, 01/15/2025 (MT Newswires) -- Eli Lilly ( LLY ) said the US Food and Drug Administration granted expanded approval for Omvoh to treat adult patients with moderate to severe active Crohn's disease in adults.

The approval is based on results from a phase 3 study that showed 53% of patients treated with Omvoh had clinical remission and 46% had visible healing of intestinal lining at one year, Eli Lilly ( LLY ) said Wednesday in a statement.

The FDA previously approved the drug in October 2023 for treatment of moderately to severely active ulcerative colitis.